These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 35898339)

  • 1. Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2 in Shanghai, February-June 2022.
    Chen X; Yan X; Sun K; Zheng N; Sun R; Zhou J; Deng X; Zhuang T; Cai J; Zhang J; Ajelli M; Yu H
    medRxiv; 2022 Jul; ():. PubMed ID: 35898339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2 in Shanghai, February-June 2022.
    Chen X; Yan X; Sun K; Zheng N; Sun R; Zhou J; Deng X; Zhuang T; Cai J; Zhang J; Ajelli M; Yu H
    Emerg Microbes Infect; 2022 Dec; 11(1):2800-2807. PubMed ID: 36205530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiological characteristics and transmission dynamics of the outbreak caused by the SARS-CoV-2 Omicron variant in Shanghai, China: a descriptive study.
    Chen Z; Deng X; Fang L; Sun K; Wu Y; Che T; Zou J; Cai J; Liu H; Wang Y; Wang T; Tian Y; Zheng N; Yan X; Sun R; Xu X; Zhou X; Ge S; Liang Y; Yi L; Yang J; Zhang J; Ajelli M; Yu H
    medRxiv; 2022 Jun; ():. PubMed ID: 35765564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral kinetics of SARS-CoV-2 following onset of COVID-19 in symptomatic patients infected with the ancestral strain and omicron BA.2 in Hong Kong: a retrospective observational study.
    Lin Y; Wu P; Tsang TK; Wong JY; Lau EHY; Yang B; Leung GM; Cowling BJ
    Lancet Microbe; 2023 Sep; 4(9):e722-e731. PubMed ID: 37659420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark.
    Hansen CH; Friis NU; Bager P; Stegger M; Fonager J; Fomsgaard A; Gram MA; Christiansen LE; Ethelberg S; Legarth R; Krause TG; Ullum H; Valentiner-Branth P
    Lancet Infect Dis; 2023 Feb; 23(2):167-176. PubMed ID: 36270311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination effects on post-infection outcomes in the Omicron BA.2 outbreak in Shanghai.
    Wu Q; Wang H; Cai J; Ai J; Li Y; Zhang H; Wang S; Sun F; Wu Y; Zhou J; Wang Y; Yu H; Zhang W
    Emerg Microbes Infect; 2023 Dec; 12(1):e2169197. PubMed ID: 36644859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong.
    Zhou R; Liu N; Li X; Peng Q; Yiu CK; Huang H; Yang D; Du Z; Kwok HY; Au KK; Cai JP; Fan-Ngai Hung I; Kai-Wang To K; Xu X; Yuen KY; Chen Z
    Lancet Reg Health West Pac; 2023 Mar; 32():100660. PubMed ID: 36591327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.
    Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Ackerson BK; Xie F; Takhar H; Ogun OA; Simmons S; Zamparo JM; Valluri SR; Jodar L; McLaughlin JM
    Lancet Respir Med; 2023 Dec; 11(12):1089-1100. PubMed ID: 37898148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts.
    Zeng T; Lu Y; Zhao Y; Guo Z; Sun S; Teng Z; Tian M; Wang J; Li S; Fan X; Wang W; Cai Y; Liao G; Liang X; He D; Wang K; Zhao S
    Respir Res; 2023 Oct; 24(1):246. PubMed ID: 37828565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiological characteristics and transmission dynamics of the outbreak caused by the SARS-CoV-2 Omicron variant in Shanghai, China: A descriptive study.
    Chen Z; Deng X; Fang L; Sun K; Wu Y; Che T; Zou J; Cai J; Liu H; Wang Y; Wang T; Tian Y; Zheng N; Yan X; Sun R; Xu X; Zhou X; Ge S; Liang Y; Yi L; Yang J; Zhang J; Ajelli M; Yu H
    Lancet Reg Health West Pac; 2022 Dec; 29():100592. PubMed ID: 36090701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transmission risks of Omicron BA.5 following inactivated COVID-19 vaccines among children and adolescents in China.
    Guo Z; Zeng T; Lu Y; Sun S; Liang X; Ran J; Wu Y; Chong MKC; Wang K; Zhao S
    Commun Med (Lond); 2024 May; 4(1):92. PubMed ID: 38762678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods.
    Link-Gelles R; Levy ME; Natarajan K; Reese SE; Naleway AL; Grannis SJ; Klein NP; DeSilva MB; Ong TC; Gaglani M; Hartmann E; Dickerson M; Stenehjem E; Kharbanda AB; Han J; Spark TL; Irving SA; Dixon BE; Zerbo O; McEvoy CE; Rao S; Raiyani C; Sloan-Aagard C; Patel P; Dascomb K; Uhlemann AC; Dunne MM; Fadel WF; Lewis N; Barron MA; Murthy K; Nanez J; Griggs EP; Grisel N; Annavajhala MK; Akinseye A; Valvi NR; Goddard K; Mamawala M; Arndorfer J; Yang DH; Embí PJ; Fireman B; Ball SW; Tenforde MW
    JAMA Netw Open; 2023 Mar; 6(3):e232598. PubMed ID: 36920396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical profile analysis of SARS-CoV-2 community infections during periods with omicron BA.2, BA.4/5, and XBB dominance in Hong Kong: a prospective cohort study.
    Wang Y; So HC; Tsang NNY; Kwok SK; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2024 Oct; ():. PubMed ID: 39419049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of BNT162b2 and Sinovac vaccines against the transmission of SARS-CoV-2 during Omicron-predominance in Hong Kong: A retrospective cohort study of COVID-19 cases.
    Zhao S; Guo Z; Sun S; Hung CT; Leung EYM; Wei Y; Wang H; Li K; Yam CHK; Chow TY; Gao J; Jia KM; Chong KC; Yeoh EK
    J Clin Virol; 2023 Sep; 166():105547. PubMed ID: 37453162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world effectiveness of the heterologous SOBERANA-02 and SOBERANA-Plus vaccine scheme in 2-11 years-old children during the SARS-CoV-2 Omicron wave in Cuba: a longitudinal case-population study.
    Toledo-Romaní ME; Valenzuela-Silva C; Montero-Díaz M; Iñiguez-Rojas L; Rodríguez-González M; Martínez-Cabrera M; Puga-Gómez R; German-Almeida A; Fernández-Castillo S; Climent-Ruiz Y; Santana-Mederos D; López-González L; Morales-Suárez I; Doroud D; Valdés-Balbín Y; García-Rivera D; Van der Stuyft P; Vérez-Bencomo V
    Lancet Reg Health Am; 2024 Jun; 34():100750. PubMed ID: 38699214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.
    Tamandjou Tchuem CR; Auvigne V; Vaux S; Montagnat C; Paireau J; Monnier Besnard S; Gabet A; Benhajkassen N; Le Strat Y; Parent Du Chatelet I; Levy-Bruhl D
    Vaccine; 2023 Mar; 41(13):2280-2288. PubMed ID: 36870880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022.
    Iuliano AD; Brunkard JM; Boehmer TK; Peterson E; Adjei S; Binder AM; Cobb S; Graff P; Hidalgo P; Panaggio MJ; Rainey JJ; Rao P; Soetebier K; Wacaster S; Ai C; Gupta V; Molinari NM; Ritchey MD
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):146-152. PubMed ID: 35085225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death.
    Huang Z; Xu S; Liu J; Wu L; Qiu J; Wang N; Ren J; Li Z; Guo X; Tao F; Chen J; Lu D; Sun X; Wang W
    BMC Med; 2022 Oct; 20(1):400. PubMed ID: 36266697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.